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Introduction
PAPA syndrome is a very rare autoinflammatory condi-
tion. Few data are nowadays available about the clinical
characteristic, the response to treatment and the
outcome of this disease.
Objectives
to analyse the data of the PAPA patients enrolled to the
Eurofever registry.
Methods
The data analysed in the study were extracted from the
Eurofever registry, which is hosted in the PRINTO
website http://www.printo.it. The patients were
included in the study in the presence of clinical mani-
festations consistent with PAPA syndrome and muta-
tions in the PSTPIP1 gene. Demographic data, clinical
manifestations and response to treatment were
analysed.
Results
In February 2013 baseline and clinical information were
available of 2567 patients from 88 centers in the Eurof-
ever registry. Of these 16 patients PAPA patients (M:F =
8:8), from 3 different centers, fulfilled the inclusion
criteria and were therefore analysed: 10 were of the same
family, in 3 patients the disease was caused by a de novo
mutation while in 3 cases the mutation was found in one
parent (not yet included in the registry). The mean age
at enrolment was 26,22 years (4 paediatric and 12 adult
patients). The mean age at disease onset was 5,7 years
(range birth - 18 years). The mean age at diagnosis was
24,5 years (range 1,8 - 57,5), with a mean delay of 18,8
years (range 2 months - 50 years). The mutations found
in the PSTPIP1 gene were V344I (1pt), E250K (1 pt),
E257G (1 pt), A230T (2 pts), and E250Q (11 pts).
The disease course was recurrent in 8 patients, while
the other 8 presented a chronic disease course with
periodic recrudesces. 15 patients presented an articu-
lar involvement during their disease course, while 11
patients presented clinical manifestations affecting the
skin (folliculitis in 8, pyoderma gangrenosum in 3,
skin abscess 8 patients); five and one patients pre-
sented only the articular and skin involvement respec-
tively. 2 patients complained with suppurative
hidradenitis while 7 out of the 16 patients presented
clinical manifestations not typical of PAPA syndrome
(psoriasis, osteolytic bone lesions, chronic renal fail-
ure, muscular abscesses, anaemia and hepatospleno-
megaly). 10 patients were treated with NSAID with
poor response while steroids caused a complete or
partial control of disease manifestations in 5 and 6
patients respectively. Two patients were treated with
methotrexate with partial response. Etanercept was
used in one patient with complete response, adalimu-
mab in 3 patients (2 partial and 1 complete respon-
ders) and anakinra in 5 patients (2 partial and 3
complete responders).
Conclusion
The study analyses the largest series of PAPA syndrome
patients described so far. The wide clinical heterogeneity
and the usual presentation with a single manifestation
might be responsible for under-recognition of the
syndrome.
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